Possible Inhibitory Effect of Erythropoiesis-Stimulating Agents at the Predialysis Stage on Early-Phase Coronary Events after Hemodialysis Initiation

Cardiorenal medicine

Nishimura M.¹  · Watanabe K.²  · Tokoro T.²  · Takatani T.²  · Yamazaki S.³  · Kitamura Y.⁴  · Nagashima T.⁴  · Kobayashi H.⁴  · Sato N.⁴  · Hashimoto T.⁴  · Ono T.⁴ 

[1] Cardiovascular Division,;Department of Nephrology, and;Department of Urology, Toujinkai Clinic, Kyoto, Japan;Department of Urology, Toujinkai Hospital, and

关键词: Hemodialysis;    Coronary plaque;    Erythropoiesis-stimulating agent;    Anemia;    Chronic kidney disease;   

DOI  :  10.1159/000448009

学科分类：心脏病和心血管学

来源: S Karger AG

【 摘 要 】

Background: We examined whether the use of erythropoiesis-stimulating agents (ESAs) to correct anemia at the predialysis stage could inhibit early-phase coronary events after hemodialysis initiation. Methods: We enrolled 242 patients with chronic kidney disease who had received continued medical treatments and initiated maintenance hemodialysis from 1 September 2000 to 31 December 2014 at Toujinkai Hospital. Patients with a previous history of blood transfusion or any cardiovascular events or interventions were excluded. The coronary events were followed for 1 year after initiation of hemodialysis. Results: Coronary events occurred in 51 of 242 patients: 10 patients had acute coronary syndrome [9 with percutaneous coronary intervention (PCI), 1 without intervention], and 41 had elective coronary revascularization (38 PCI and 3 coronary artery bypass graft). ESA was administered in 118 of 242 patients (48.8%). In stepwise logistic analysis, coronary events were positively associated with nonuse of ESA at the predialysis stage (odds ratio 2.66, p = 0.005) and diabetes mellitus (odds ratio 5.33, p < 0.001). When dividing the patients into 4 subgroups by blood hemoglobin (Hb) level (8.5 g/dl) and the use/nonuse of ESA, coronary event-free survival rates were higher (p = 0.005) in those with Hb ≥8.5 g/dl, ESA+ (86.6%, n = 82) and tended to be higher (p = 0.055) in those with Hb <8.5 g/dl, ESA+ (86.1%, n = 36) than in patients with Hb <8.5 g/dl, ESA- (68.6%, n = 86) in a Kaplan-Meier analysis. Conclusions: The use of ESA to correct anemia at the predialysis stage may inhibit early-phase coronary events after hemodialysis initiation.

【 授权许可】

CC BY